Pharmaceutical Executive spoke with Dr. Richard Graham, chairman and co-founder of TruTechnologies about FDA’s new program ...

This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...

Formulary decisions commonly restrict access to T2D and weight loss, creating coverage blind spots as GLP-1 trials mature across broader cardiometabolic and organ-protection indications. Utilization ...

Since then, that mindset has continued to grow at AbbVie.

Specialty pharma launches depend heavily on data from outside the organization. Distributors, third-party logistics providers ...

An FDA advisory panel voted to recommend six of seven unapproved peptides for compounding access, raising concerns about its ...

Learn why reshoring and tariff exposure are accelerating the trend toward manufacturing in the market where a product is sold. Understand the significance of the Section 301 investigation into Germany ...

Vogenx estimates net proceeds of approximately $67.8 million based on an assumed offering price of $12.00 per share. 3 Vogenx is a clinical-stage biopharmaceutical company focused on disorders linked ...

Pharmaceutical Executive spoke with John Standford, executive director of Incubate, about the rise of China as an R&D partner and the US government’s responses. According to him, years of investment ...

FDA approval used the 505(b)(2) pathway and Phase III Luminous results to support efficacy, safety characterization, and adhesive performance in women with BMI <30 kg/m². Contraceptive efficacy in the ...

CTGTAC endorsed that single-arm Ignyte response rate and durability support clinically meaningful systemic antitumor activity attributable to intratumoral RP1 combined with nivolumab in ...

Understand how patient advocacy groups are weighing MFN's affordability promise against other access issues like Medicaid community engagement requirements. Learn why international reference pricing ...